The level of antibodies against the delta strain of the virus is less than one-fifth of the level of antibodies produced against the original type of coronavirus in the body of a person receiving the Pfizer-Bioentech vaccine. The data came from a study published in the world-renowned Lancet magazine, according to a report by Indian media outlet NDTV.
The antibodies that are produced in the body as a result of the vaccine, when the coronavirus enters the body, detects and inactivates the virus. Studies have shown that the effectiveness of Pfizer vaccine antibodies decreases as vaccinators age. Its efficiency also decreases with time. These observations reinforce the rationale for giving booster doses to protect people at risk.
The results of the study support current plans to reduce the time interval between two doses of tick in the UK. UK authorities have recently found that the first coronavirus to be found in Kent, UK, was among the Pfizer vaccinators. The level of antibody produced against the 1.1.6 (alpha) type is not the same as that against the delta type B.1.617.2 (Indian type). Based on this, they have decided to reduce the time interval between two doses of the vaccine.
Researchers at the Francis Creek Institute in the UK led the study. Researchers say antibody levels alone do not provide evidence of vaccine effectiveness. More research is needed in this regard. Low doses of coronavirus inactivating antibodies may protect against Covid-19.
The study analyzed the levels of antibodies in the blood of 250 healthy people who took two doses of the Pfizer vaccine. The interval between taking two doses of the vaccine in these individuals was up to three months.
The study was conducted on five types of SARS-COV-2. The ability of the virus to enter the cells of the human body is tested to see how much it can prevent. They then compared the concentration of this ‘neutralizing antibody’ in all variants.
Past clinical trials have shown that high levels of antibody concentration indicate the effectiveness of the vaccine and protection against Covid-19.
Studies have shown that the levels of neutralizing antibodies in the blood of two doses of Pfizer vaccinators are less than one-fifth of those in the B1.617.2 type compared to the original virus. For those who have taken only one dose, their antibody response is even lower.
After taking a single dose of the Pfizer vaccine, 69 percent of people have a neutralizing antibody response against the main strain of the virus. There it drops to 50 percent against the B1.1.6 type, down to 32 percent against the B1.617.2 type, and down to the B1.351 or beta variant (first seen in South Africa). 25 percent.
In each case, the antibody levels are lower with age, but there is no difference in weight between men and women or body weight.
Emma Wall, an infectious disease consultant at the University College London Hospitals NHS Foundation Trust (UCLH), said: ‘It will take some more time for the virus to come to us. So we have to be careful and be agile.
He said the study was carried out keeping in mind the need to present evidence of changing risks and take precautionary measures in the event of an epidemic.
According to the researchers, the most important thing is that the vaccine has saved a large number of people with corona from being hospitalized.
Studies have suggested that a second dose of the vaccine be given in the shortest possible time, and that those who are less resistant to these new variants be given a booster dose.